Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer

Lung Cancer Clinical Trial

— CCA-MPLC  

Official title:

An Exploratory Study on the Safety and Efficacy of Cryoablation Combined With Camrelizumab and Apatinib in the Treatment of Multiprimary Lung Cancer With Non-known Driving Genes

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04201990
• Other study ID #: 2019-62
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: December 2019
• Est. completion date: December 2022

Study information

• Verified date: December 2019
• Source: Guangzhou Institute of Respiratory Disease
• Contact: Shiyue Li, MD
• Phone: 8620-83062896
• Email: lishiyue[@]188.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Objective: This study is to observe the safety and therapeutic effect of cryoablation combined with pd-1 antibody immunotherapy and anti-angiogenesis therapy in multiple primary lung cancer (MPLC) patients.

Methods: In this study, 20 patients with MPLC who conform to the admission criteria are enrolled and began to receive treatment with Camrelizumab combined with Apatinib after cryoablation.

Description:

Subjects who meet the admission criteria will be treated with Camrelizumab and Apatinib until disease progression, intolerable toxicity, death, withdrawal of the patient or the researchers determined that the drug must be discontinued.

The primary end point of this study is safety of cryoablation combined with carillizumab and apatinib for MPLC. The secondary endpoints include objective response rate, disease control rate, time to progression, progression free survival and overall survival. Exploratory endpoint is to explore biomarkers in tumor tissue and blood that could potentially predict the efficacy of Camrelizumab and Apatinib.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: December 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. clinical and pathological diagnosis of muitiple primary lung cancer.

2. more than three pulmonary nodules and without lymph node metastasis.

3. the maximum lesion less than three centimeters in diameter.

4. No more than one operation, and remains more than two pulmonary nodules which pathological confirmed were MIA or AIS.

5. at least one measurable lesion conforming to RECIST v1.1 standard was left after cryotherapy.

6. male or female, age 18 to 75 years old.

7. the ECOG PS score was 0 or 1.

8. expected survival is more than 12 weeks.

9. functions of vital organs and bone marrow meet the following requirements: A. ANC =1.5× 109/L, PLT =100× 109/L, HGB =9 g/dL; B. TBIL =1.5 ULN, ALT and/or AST =2.5 ULN, ALB =2.8 g/dL; C. Cr =1.5× ULN, or creatinine clearance rate =40 mL/min

10. subject and subject's sexual partner shall use a medically approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period.

11. subject must sign theinformed consent.

Exclusion Criteria:

1. patients with EGFR mutations and ALK rearrangement.

2. cannot be treated with cryoablation: diffuse lesions in both lungs, extensive pleural metastasis with large amount of pleural effusion, tumor adjacent to mediastinal large vessels or surrounding large vessels.

3. have previously received anti-pd-1, anti-pd-l1, anti-ctla-4 antibodies or any other antibodies or drugs that target T cell co-stimulation or immune checkpoint pathways.

4. received the following treatment Within four weeks before enrollment:

• received systemic anti-tumor therapy, such as chemotherapy, targeted therapy and immunotherapy;

• receive any investigational medication;

• receive a large dose of immunosuppressive drugs (systemic glucocorticoid exceeding 10 mg/ temprednisone or its equivalent);

• receive live attenuated vaccine;

• major surgery or unhealed surgical wounds, ulcers, or fractures.

5. known or suspected active autoimmune diseases (congenital or acquired).

6. allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.

7. allergy to any component of monoclonal antibody preparation.

8. interstitial lung disease.

9. suffering from other uncontrolled serious diseases, including but not limited to:

• severe infections in the active phase or with poor clinical control;

• HIV infection (HIV antibody positive);

• acute or chronic active hepatitis B (HBV DNA positive) or acute or chronic active hepatitis C (HCV antibody positive);

• active tuberculosis;

• grade iii-iv congestive heart failure (New York cardiology association classification), poorly controlled and clinically significant arrhythmia;

• uncontrolled arterial hypertension (systolic blood pressure =160mmHg or diastolic blood pressure =100mmHg);

• any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, occurred within 6 months;

• diseases requiring anticoagulant therapy with farfarin (coumarin);

• uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued bisphosphate therapy;

• accompanied by other malignant tumors (except those that have been cured, such as carcinoma in situ of the cervix, non-melanoma skin cancer, etc.).

10. The participants were judged to be unsuitable for the study by investigator.

11. Pregnant or nursing women.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• Camrelizumab and Apatinib
Camrelizumab, iv, Q3W; Apatinib, po, QD

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
ShiYue Li

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	biomarker	To explore biomarkers in tumor tissue and blood that could potentially predict the efficacy of Camrelizumab and Apatinib like PD-L1, ctDNA, CEA, CA125, CA153.	three months
Primary	Safety score	The occurrence of grade 3 to 5 adverse reactions was assessed by CTC AE v5.0	three weeks
Secondary	ORR	objective response rate	six weeks
Secondary	DCR	Disease control rate	six weeks
Secondary	PFS	progression free survival	six weeks
Secondary	OS	Overall survival	six weeks
Secondary	DOR	Duration of response	six weeks